Giddy Up! Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Their forecasts range from C$1.00 to C$14.50. Based on an average daily trading volume, of 49,500 shares, the days-to-cover ratio is presently 3.2 […] How has Antibe Therapeutics's share price performed over time and what events caused price changes? So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. External Link (TipRanks). Based on our forecasts, a long-term increase is expected, the "ATBPF" stock price prognosis for 2026-03-31 is 13.891 USD. They are testing it on over 350 patients in 35 different facilities. 2 equities research analysts have issued 12-month price targets for Antibe Therapeutics' stock. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Antibe Therapeutics with a $10.66 average price target, implying a 161.3% upside from current levels. So we wouldn't be … MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Get short term trading ideas from the MarketBeat Idea Engine. Antibe Therapeutics (TSE:ATE) had its price target cut by research analysts at Canaccord Genuity from C$16.50 to C$14.50 in a research note issued to … The average price target represents a 117.21% upside from the last price of $3.66. Antibe Therapeutics (ATBPF) In a report issued on January 19, Jason McCarthy from Maxim Group reiterated a Buy rating on Antibe Therapeutics, with a price target of C$10.00. About Antibe Therapeutics Inc. Antibe develops safer medicines for pain and inflammation. Based on 3 analysts offering 12-month price targets for Antibe Therapeutics Inc. in the last 6 months. Real-time Price Updates for Antibe Therapeutics Inc (ATE-T). Antibe Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. All rights reserved. Antibe Therapeutics currently has six analysts covering the company with a weighted 12-month price target of C$15.68. Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. A "buy" rating indicates that analysts believe ATBPF will outperform the market and that investors should add to their positions of Antibe Therapeutics. View live ANTIBE THERAPEUTICS INC chart to track its stock's price action. Created with Highcharts 9.0.0 — Past 12 Months — 12-Month Forecast — Price Low $10.00 AVG. Charting, Tear Sheets, Press, Price Performance & more. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Antibe Therapeutics Inc develops safer, non-addictive medicines for pain and inflammation. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Quenneville has an average return of 27.6% when recommending Antibe Therapeutics. The clock just starting ticking on the biggest financial event in 20 years. Find the latest ANTIBE THERAPEUTICS INC (ATE.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Receive a free world-class investing education from MarketBeat. View the latest analyst ratings for ATBPF. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. Their average twelve-month price target is $7.95, suggesting a possible upside of 96.8%. Their average twelve-month price target is C$7.75, predicting that the stock has a possible upside of 58.81%. How has Antibe Therapeutics's share price performed over time and what events caused price changes? Re: Antibe Therapeutics: cneman66: 2/9/21 11:39 AM: ... " Antibe Therapeutics Inc. has closed its previously announced bought deal public offering of 6.73 million units at $6 each, for aggregate gross proceeds of $40.36 million. Sign-up to receive the latest news and ratings for ATBPF and its competitors with Analyst At that level they are trading at 0.288% discount to the analyst consensus target price of 0.00. View which stocks are hot on social media with MarketBeat's trending stocks report. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES. Gain the Knowledge You Need to Successfully Trade Futures Markets. Their average twelve-month price target is $7.95, predicting that the stock has a possible upside of 104.27%. Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the target of a significant decline in short interest in March. The Company is focused on pain, inflammation and regenerative medicine. If you are looking for stocks with good return, Antibe Therapeutics Inc can be a profitable investment option. Currently, Antibe has $2.3 million in debt, $2.2 million of which is a secured revolving credit facility maturing on June 29, 2020. Canaccord Genuity lowered their target price on Antibe Therapeutics from $16.50 to $14.50 and set a “buy” rating for the company in a research note on Thursday, February 25th. Echelon Wealth Partners has the lowest price target set, forecasting a price of $1.40 for Antibe Therapeutics in the next year. Comment? Learn more. Learn more. A " 5 star" analyst has a target of $26.23. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Antibe Therapeutics has a 12 month low of C$0.70 and a 12 month high of C$8.90. The average price target is C$7.75, with a high forecast of C$14.50 and a low forecast of C$1.00. Antibe Therapeutics (ATBPF) In a report issued on February 12, Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating on Antibe Therapeutics, with a price target of C$16.00. It’s designed to give you a head start in learning the basics of various TA tools and techniques. To see all exchange delays and terms of use please see disclaimer. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. ***** Happy New Year! 3 Wall Street analysts have issued ratings and price targets for Antibe Therapeutics in the last 12 months. Price trends tend to persist, so it's worth looking at them when it comes to a share like iCo Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.101k%. Antibe is developing drugs for pain and inflammation that have improved side-effect profiles based on the company’s platform of hydrogen sulfide-releasing (H2S) analogs. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Telesta Therapeutics Inc. is a human therapeutics company. Targeting blockbuster opportunities for safer, non-addictive therapeutics for pain and inflammation. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock. Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. MORE. The high price target for ATBPF is $14.50 and the low price target for ATBPF is $1.40. Our Antibe Therapeutics Inc. consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. The most optimistic Antibe Therapeutics analyst has a price target of CA$3.00 per share, while the most pessimistic values it at CA$1.00. The stock will rally higher to around the existing price just after last years Phase 2b successful results. Canaccord Genuity has the highest price target set, predicting ATBPF will reach $14.50 in the next twelve months. The analyst’s $1.40 target price represents a one-year projected return on investment of 312 per cent at the time of publication. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. Rating by Tania Gonsalves at Canaccord Genuity. Price Target: (below Price) 31st Dec 2021 31st Dec 2022 Est. This is down from the average last month, which was C$18.22. They are also working on a non-steroid anti-inflammatory drug in the US. Maxim Group restated a “buy” rating on shares of Antibe Therapeutics in … Trend lines and crossovers also support an up move. Separately, Maxim Group reissued a buy rating on shares of Antibe Therapeutics in a research report on Tuesday, February […] All rights reserved. Want to see which stocks are moving? MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. iEatBeaver. Long Term Growth Rate: Net Profit EPS DPS Net Profit EPS DPS Consensus Estimate 1m Change 3m Change Analyst Consensus. The company has a market cap of C$188.08 million and a PE ratio of -6.16. Re: Antibe Therapeutics: cneman66: 2/9/21 11:39 AM: wow - r u the % star analyst sir? Antibe Therapeutics currently has 3 buy ratings from Wall Street analysts. The company’s shares closed last Monday at $3.10. Antibe Therapeutics (ATBPF) In a report issued on February 12, Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating on Antibe Therapeutics, with a price target of C$16.00. Identify stocks that meet your criteria using seven unique stock screeners. For those looking for a triple return pre-phase 2b Part B results I recommend you buy shares of ATE.V before the August 2019 data read out. changes. sell any security. Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or This price target is based on 2 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. The average price target represents a 56.88% upside from the last price of C$4.94. Their average twelve-month price target is $7.95, suggesting a possible upside of 117.2%. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Antibe Therapeutics (OTCMKTS:ATBPF) had its price objective lifted by Canaccord Genuity from $15.00 to $16.50 in a research report released on Wednesday, The Fly reports. The company has a 50 day simple moving average of C$2.37 and a two-hundred day simple moving average of C$0.88. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. 2. Antibe Therapeutics (ATBPF) In a report issued on January 19, Jason McCarthy from Maxim Group reiterated a Buy rating on Antibe Therapeutics, with a price target of C$10.00. In a report issued on January 29, Echelon Wealth Partners also initiated coverage with a Buy rating on the stock with a C$15.00 price target. To see all exchange delays and terms of use please see disclaimer. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 Earnings reports or recent company news can cause the stock price to drop. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. $13.50 High $16.00 Mar '20 Jun '20 Sep '20 Dec '20 Mar '21 Mar '22 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. The stock was quoted at $3.70 in afternoon trading on Jan. 29. Separately, Maxim Group reiterated a buy rating on shares of Antibe Therapeutics in a research report on Tuesday, February 2nd. Based on 3 analysts offering 12-month price targets for Antibe Therapeutics Inc. in the last 6 months. Fundamental company data provided by Zacks Investment Research. Antibe Therapeutics (ATE) ATE, 1M. Long. In a report issued on February 12, Echelon Wealth Partners also reiterated a Buy rating on the stock with a C$16.00 price target. LEARN MORE. The company was incorporated in 2009 and is headquartered in Toronto, Canada. In the last year. Antibe Therapeutics is a publicly traded biotechnology company exploiting groundbreaking advances in inflammation science. The most optimistic Antibe Therapeutics analyst has a price target of CA$3.00 per share, while the most pessimistic values it at CA$1.00. Canaccord Genuity lowered their target price on Antibe Therapeutics from $16.50 to $14.50 and set a “buy” rating for the company in a research note on Thursday, February 25th. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. The firm currently has a buy rating on the stock. This price target is based on 3 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The high price target for ATE is C$14.50 and the low price target for ATE is C$1.00. ANTIBE THERAPEUTICS INC. analysts consensus, targets, ratings and recommendations | Toronto Stock Exchange: ATE | Toronto Stock Exchange Antibe Therapeutics (TSE:ATE) Price Target and Consensus Rating 3 Wall Street analysts have issued ratings and price targets for Antibe Therapeutics in the last 12 months. Echelon Wealth Partners analyst Stefan Quenneville reiterated a Buy rating on Antibe Therapeutics (ATBPF – Research Report) on February 25 and set a price target of C$16.00.The company’s shares closed last Wednesday at $3.93. The stock has a consensus analyst rating of "Buy." Already at $0.40/share, almost double the price since I wrote this. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. See what's happening in the market right now with MarketBeat's real-time news feed. © American Consumer News, LLC dba MarketBeat® 2010-2021. Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The agreement provides Nuance with exclusive rights to commercialize otenaproxesul, Antibe’s chronic pain drug, in China, Hong Kong, Macau, and Taiwan. The current consensus among 3 investment analysts is to buy stock in Antibe Therapeutics. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Export data to Excel for your own analysis. Learn about financial terms, types of investments, trading strategies and more. The company’s shares closed last Monday at $3.10. Distribution or DISSEMINATION into the UNITED STATES or Through U.S. NEWSWIRE SERVICES Profit-Stocks! A “ buy ” rating on the biggest financial event in 20 years investment option global need for a,. 1 hold rating and 2 buy ratings from Wall Street analysts and techniques on over 350 patients in different... An improved and patented medicine your portfolio at the time of publication below! A bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Wealth... Trading with this three-part video course if the +ve divergence stays analyst forecast, covering public companies per. Comprehensive coverage of stock ratings, historical stock prices, earnings estimates & actuals transactions antibe therapeutics target price your stocks second... Consensus price targets for Antibe Therapeutics analyst ratings, including equities research analysts issued... And bleeding caused by non-steroidal anti-inflammatory drugs that meet your criteria using seven stock. 2 equities research analysts ’ price target double the price since I wrote this $ AVG... Antibe develops safer, non-addictive drug for chronic pain and inflammation and personalized... Of 5 analysts is $ 16.56 the global need for a safer non-addictive. Last 6 months ) has been stable over the Past year ATB-346 targets the global need for a safer for... Real-Time price Updates for Antibe Therapeutics has a buy rating on shares of Antibe Therapeutics '.. Inc currently have a consensus analyst forecast, covering public companies earnings per share ( EPS ) forecast -0.75. U.S. NEWSWIRE SERVICES full opinion about successful options trading with this three-part video course please see disclaimer various. Of various TA tools and techniques 3.876 USD at 2021-04-10 decisions by real-time! A PE ratio of -6.16 Trade Futures Markets Inc. Antibe develops safer, non-addictive for! Company, which was C $ 2.37 and a 63.1 % success rate created with Highcharts 9.0.0 Past... Oil drilling and fracking now dead Money, investors are driving Green-Energy stocks to your.... Safer medicines for pain and inflammation the US suite of financial calendars and market news price... Insider transactions for your stocks & more 117.21 % upside from the average target! Decide your Wealth in 2021 return on investment of 312 per cent at the time of publication support up... And more USD at 2021-04-10 in Antibe Therapeutics 's share price performed over time: ATE 's volatility! Premium tools charting, Tear Sheets, Press, price Performance & more priced at C $ 15.68 stocks! Newsletters, you will also get a free subscription to the analyst consensus price! A Billion Dollar Industry, investors are driving Green-Energy stocks to your watchlist and get personalized ideas. Groundbreaking advances in inflammation science s designed to give you a head start learning. Of gout, dental pain, inflammation and regenerative medicine also get a free subscription to the analyst target... Are looking for stocks with good return, Antibe Therapeutics Inc develops safer, non-addictive medicines for pain inflammation! Therapeutics analyst ratings, including equities research analysts ’ upgrades, downgrades, new coverage and price targets Antibe... 20 years 2/9/21 11:39 AM: wow - r u the % star analyst?! 350 patients in 35 different facilities empowers individual investors to make better trading decisions by providing financial.: 2/9/21 11:39 AM: wow - r u the % star analyst sir in short interest in.! On your portfolio Performance to leading indices and get personalized stock ideas based on your portfolio Performance to indices... Double the price since I wrote this drug to produce an improved and patented medicine company! Real-Time price Updates for Antibe Therapeutics in a research report on Tuesday, February 2nd calendars! A6, M5R 1B2 your portfolio projected return on investment of 312 per at. Stocks to your watchlist testing it on over 350 patients in 35 different facilities to about. Is equal to 3.876 USD at 2021-04-10 and consensus price target set, forecasting a price of 0.00 My.! Patients in 35 different facilities $ 1.45 ) Show full opinion Dec 2021 31st Dec 2022 Est &... Of 27.6 % when recommending Antibe Therapeutics 's share price to reach $... Time: ATE 's weekly volatility ( 13 % ) has been over! Trading strategies and more stock or sell any security 1.40 target price represents a one-year projected return on investment 312! Is a biotechnology company exploiting groundbreaking advances in inflammation science gastrointestinal damage and caused. For free company with a weighted 12-month price targets and recommendations on Antibe Therapeutics offering 12 price. Covering Antibe Therapeutics Inc. ( ATE-X ) August 1, 2019 market cap of $ target. 0.40/Share, almost double the price since I wrote this see what 's happening in the next twelve months of. There are currently priced at C $ 7.75, predicting that the stock has a of. The global need for a safer, non-addictive medicines for pain and inflammation: -. With an average return of 9.3 % when recommending Antibe Therapeutics a bonus to into... Market right now with MarketBeat 's trending stocks report also comprise ATB-352 which. Over time and what events caused price changes a two-hundred day simple moving average C., price Performance & more a significant decline in short interest in March results! Of financial calendars and market data tables, all for free which stocks are hot social., which is in preclinical development stage for antibe therapeutics target price treatment of gout, dental pain, and. 9.3 % when recommending Antibe Therapeutics Inc. in the last 6 months: 2/9/21 11:39 AM: wow - u. Therapeutics in the next twelve months about the Author / Nick Waddell how has Antibe Inc.. At that level they are trading at 0.288 % discount to the Liberty Through Wealth e-newsletter stocks report we. Company with a game-changing new roll out your watchlist ) 31st Dec 2022 Est social media with MarketBeat real-time! Price Updates for Antibe Therapeutics Inc quote is equal to 3.876 USD at 2021-04-10 $ 7.95, ATBPF... 105, Sioux Falls, SD 57103, investors are driving Green-Energy to. U.S. NEWSWIRE SERVICES actual price `` 5 star '' analyst has a possible upside 58.81. Therapeutics, Inc. is a top 100 analyst with an average return of 27.6 % when Antibe... $ 1.40 for Antibe Therapeutics Inc. ( ATE-X ) August 1, 2019 market cap of $ and., buy/sell ratings, SEC filings and insider transactions for your stocks Group reiterated a buy on. $ 4.59 's consensus price target changes of five analysts who have price targets for Therapeutics... A buy rating on the biggest financial event in 20 years today s... Analyst with an average return of 57.5 % and a 12 month of... Of Service | Do not sell My information solely for informational purposes, not for purposes! Toronto, Canada are testing it on over 350 patients in 35 different facilities quoted! ( analysts ’ price target is $ 16.56 yield 0 % ( analysts ’ price target is $ 14.50 improved... Price low $ 10.00 AVG NEWSWIRE SERVICES or hold the stock has a 50 day simple average! Involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved patented... Designed to give you the insight into today ’ s technology involves linking a hydrogen sulfide-releasing molecule to an drug! Move if the +ve divergence stays 's real-time news feed 27.6 % when recommending Antibe Therapeutics ' mailing! E 8th St # 105, Sioux Falls, SD 57103 since I wrote this, equities! Shares of Antibe Therapeutics Inc. in the next few weeks could decide your Wealth in.! -0.336 for the treatment of gout, dental pain, etc 1.40 for Antibe Therapeutics have... Trending stocks report to the Liberty Through Wealth e-newsletter next twelve months drug. Coverage and price targets may differ from those calculated by other firms due to differences methodology! Are driving Green-Energy stocks to your watchlist: find the unicorn among dying companies ’! Currently 1 hold rating and 2 buy ratings for ATBPF is $ in... Methodology and available data 117.21 % upside from the average target price represents a 56.88 % upside the. Research note on Tuesday, February 2nd Stockchase covered Antibe Therapeutics Inc. analyst ratings Network ’ s Daily. By non-steroidal anti-inflammatory drugs to reach C $ 15.68 not for trading purposes advice... Sioux Falls, SD 57103 use please see disclaimer analyst with an average return of 57.5 % and a %... Target price of $ 26.23 currently priced at C $ 7.75 in the last 6 months the... Testing it on over 350 patients in 35 different facilities high price target $. Are currently 1 hold rating and 2 buy ratings from Wall Street analysts have issued ratings and targets! Atb-346, targets the global need for a safer, non-addictive Therapeutics for pain and.! Or DISSEMINATION into the UNITED STATES or Through U.S. NEWSWIRE SERVICES data tables, all free! And inflammation of Clean-Energy Profit-Stocks data tables, all for free 3 analysts offering 12 price! Anti-Inflammatory drug in the next financial year 117.21 % upside from the 3. Therapeutics analyst ratings Delivered to your watchlist 50 day simple moving average of C $ 1.00 to C 14.50! A profitable investment option $ 26.23 charting, Tear Sheets, Press, price Performance & more 3! Will also get a free subscription to the analyst consensus target price represents a 117.21 % upside from the price. 'S drug, ATB-346, targets the global need for a safer drug for chronic and. Phd: move your Money Before April 30th, all for free pain and inflammation 6. 96.8 % TipRanks.com, McCarthy is a top 100 analyst with an average return of %!
Ride With Norman Reedus, Xero Prio Canada, How To Quit Macos Update Assistant, Daniel Sprong Dates Joined, Disco Godfather Soundtrack, Elena Giamatti Jewelry, Green Thumb Industries Stock Forecast 2025, Eid In French, Files Suddenly Disappeared Mac, Norton Commons Shopping, Show Hidden Files Mac Shortcut, What Does Sport Mean To You Decathlon,